Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 201–300 of 1,001
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
Deng, Z., Tian, Y., Song, J., An, G., & Yang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887125 · Cited by 121
“The CD4+ T cell response is dominated by the Th1based immune response as well as interferon-g produced by CD4+ and CD8+ T cells (85, 86).”
BackgroundVerbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.041 · Cited by 132
Donia, M., Andersen, R. S., Kjeldsen, J. W., Fagone, P., Ahmad, S. M., Nicoletti, F., Andersen, M. H., Straten, P. T., & Svane, I. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2956 · Cited by 138
“Recently, it was shown in three independent murine models that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4þ T cells (41).”
Veatch, J. R., Lee, S. M., Fitzgibbon, M., Chow, I.-T., Jesernig, B., Schmitt, T., Kong, Y. Y., Kargl, J., Houghton, A. M., Thompson, J. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98689 · Cited by 125
“Most studies have focused on neoantigen-reactive CD8+ T cells; however, recent work in murine models has highlighted the importance of local and systemic CD4+ T cells in tumor rejection (24, 25).”
Synthetic nanovaccines for immunotherapy
Luo, M., Samandi, L. Z., Wang, Z., Chen, Z. J., & Gao, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.033 · Cited by 129
“Incorporation of these neoantigens into cationic lipids or nanoparticles can stimulate antigen-speci fi c anti-tumor e ff ects [103,133,138], which is important to overcome the relatively low immunogenicity of these neoantigens.”
Pham, C. D., Flores, C. T., Yang, C., Pinheiro, E. M., Yearley, J. H., Sayour, E. J., Pei, Y., Moore, C., McLendon, R. E., Huang, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0713 · Cited by 137
“Recent findings have also identified predominant drivers of immune response to be linked to tumorspecific mutations recognized by CD4þ cells (34).”
BackgroundNew viral vectors for infectious diseases and cancer
Sasso, E., D’Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., & Nicosia, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101430 · Cited by 134
“vaccine encoding five neoantigens has been shown to be highly effective in a model of lung metastases [191].”
BackgroundMa, L., Diao, L., Peng, Z., Jia, Y., Xie, H., Li, B., Ma, J., Zhang, M., Cheng, L., Ding, D., et al. (2021) · Advanced Materials · doi:10.1002/adma.202104849 · Cited by 140
Kilian, M., Sheinin, R., Tan, C. L., Friedrich, M., Krämer, C., Kaminitz, A., Sanghvi, K., Lindner, K. A. M., Chih, Y., Cichon, F., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.007 · Cited by 135
Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy
Wang, W., Liu, Z., Zhou, X., Guo, Z., Zhang, J., Zhu, P., Yao, S., & Zhu, M. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.11.009 · Cited by 130
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Peptide vaccines in cancer — old concept revisited
Kumai, T., Kobayashi, H., Harabuchi, Y., & Celis, E. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.11.001 · Cited by 120
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 131
Cancer vaccines: current status and future directions
Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 135
“[37–40].”
K27M-mutant histone-3 as a novel target for glioma immunotherapy
Ochs, K., Ott, M., Bunse, T., Sahm, F., Bunse, L., Deumelandt, K., Sonner, J. K., Keil, M., von Deimling, A., Wick, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328340 · Cited by 125
“For most cancer vaccines, a combination of several peptides targeting various epitopes is thought to be favorable to induce effective antitumor immune responses.(13) For H3K27M, a single Figure 2.”
BackgroundMolecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
Lee, S., Zhao, L., Rojas, C., Bateman, N. W., Yao, H., Lara, O. D., Celestino, J., Morgan, M., Nguyen, T., Conrads, K. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.066 · Cited by 130
“…have been considered for immunotherapeutic strategies, and a high correlation has been reported between tumor mutations and clinical benefits of immunotherapy targeting neoantigens in various solid tumors (Snyder et al., 2014) and in preclinical studies (Gubin et al., 2014; Kreiter et al., 2015).”
BackgroundFehlings, M., Simoni, Y., Penny, H. L., Becht, E., Loh, C. Y., Gubin, M. M., Ward, J. P., Wong, S. C., Schreiber, R. D., & Newell, E. W. (2017) · Nature Communications · doi:10.1038/s41467-017-00627-z · Cited by 115
Evolutionary dynamics of neoantigens in growing tumors
Lakatos, E., Williams, M. J., Schenck, R. O., Cross, W. C. H., Househam, J., Zapata, L., Werner, B., Gatenbee, C., Robertson-Tessi, M., Barnes, C. P., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0687-1 · Cited by 121
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Bullock, T. N. J. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00734-4 · Cited by 123
Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 127
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
Mandal, R., & Chan, T. A.-T. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0146 · Cited by 128
Roufas, C., Chasiotis, D., Makris, A., Efstathiades, C., Dimopoulos, C., & Zaravinos, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00027 · Cited by 125
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction
Müller, M., Huber, F., Arnaud, M., Kraemer, A. I., Altimiras, E. R., Michaux, J., Taillandier-Coindard, M., Chiffelle, J., Murgues, B., Gehret, T., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.002 · Cited by 121
Zhang, L. L., Xie, X.-X., Liu, D., Xu, Z. P., & Liu, R. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.015 · Cited by 113
Directing Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 156
“Several preclinical studies demonstrated that neoantigen-directed vaccination can increase tumor antigen–specific T-cell infiltration (72, 73).”
BackgroundChen, X., Yang, J., Wang, L., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.38742 · Cited by 106
“Surprisingly, when it comes to personalized neoantigen vaccines, it has been suggested that the majority of the immunogenic mutanome is recognized by CD4+ T cells in tumor-bearing C57BL/6 mice [62], further emphasizing the necessity of involving CD4+ T cell responses in anti-tumor immunity.”
BackgroundEsprit, A., de Mey, W., Bahadur Shahi, R., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 103
“Neo-epitopes that are restricted to MHC-II, antigen-presenting molecules that are mainly expressed on professional APCs, including dendritic cells (DCs), macrophages and B cells [49], have been identified in various mouse tumor models [50] as well as in cancer patients [51].”
BackgroundHLA and proteasome expression body map
Boegel, S., Löwer, M., Bukur, T., Sorn, P., Castle, J. C., & Şahin, U. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0354-x · Cited by 120
“, neo-epitopes arising from mutations [1]) and foreign (e.”
BackgroundSelf-citationZapata, L., Pich, O., Serrano, L., Kondrashov, F. A., Ossowski, S., & Schaefer, M. H. (2018) · Genome biology · doi:10.1186/s13059-018-1434-0 · Cited by 135
“The strong negative selection of an MHC class II modulator is compelling given recent evidence highlighting the importance of (MHC class II-binding) CD4(+) T cells in recognizing immunogenic mutations in cancer genomes [71].”
BackgroundDuperret, E. K., Perales-Puchalt, A., Stoltz, R., G.H., H., Mandloi, N., Barlow, J., Chaudhuri, A., Sardesai, N. Y., & Weiner, D. B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0283 · Cited by 108
“This induction of CD4þ T-cell responses occurs despite the fact that the epitopes were selected in silico for high MHCI binding affinity (3, 4, 6).”
BackgroundResultLaheurte, C., Dosset, M., Vernerey, D., Boullerot, L., Gaugler, B., Gravelin, E., Kaulek, V., Jacquin, M., Cuche, L., Eberst, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0531-5 · Cited by 115
Darragh, L. B., Knitz, M. W., Hu, J., Clambey, E. T., Backus, J., Dumit, A., Samedi, V., Bubak, A. N., Greene, C. S., Waxweiler, T. V., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00450-6 · Cited by 114
“Although CD8 + T cells are primed through interaction with MHC I, the importance of CD4 + T cell priming for an enhanced and sustained CD8 + T cell response is well-documented 44,45 .”
Cancer vaccines and the future of immunotherapy
Pail, O., Lin, M. J., Anagnostou, T., Brown, B. D., & Brody, J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00553-7 · Cited by 116
Xu, C., Hong, H., Lee, Y., Park, K. S., Sun, M., Wang, T., Aikins, M. E., Xu, Y., & Moon, J. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c05062 · Cited by 107
Yang, Y., Zhou, T., Chen, X., Li, J., Pan, J., He, X., Lin, L., Shi, Y., Feng, W., Xiong, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003790 · Cited by 104
“0/.”
Weyant, K. B., Oloyede, A., Pal, S., Liao, J., Jesus, M. R.-D., Jaroentomeechai, T., Moeller, T. D., Hoang-Phou, S. A., Gilmore, S. F., Singh, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36101-2 · Cited by 103
Poschke, I., Faryna, M., Bergmann, F., Flossdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T., Ehrenberg, R., Volkmar, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240859 · Cited by 100
Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors
Zhivaki, D., Kennedy, S. N., Park, J., Borriello, F., Devant, P., Cao, A., Bahleda, K. M., Murphy, S. M., Aubin, C., Evavold, C. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.026 · Cited by 109
Tardón, M. C., Allard, M., Dutoit, V., Dietrich, P., & Walker, P. R. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.007 · Cited by 110
Multi-antigen spherical nucleic acid cancer vaccines
Teplensky, M. H., Evangelopoulos, M., Dittmar, J. W., Forsyth, C. M., Sinegra, A. J., Wang, S., & Mirkin, C. A. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-01000-2 · Cited by 107
Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy
Kelderman, S., Schumacher, T. N., & Kvistborg, P. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.012 · Cited by 104
“Furthermore, work from Kreiter et al. (2015) has shown that MHC class II-restricted T cell responses can play an important role in tumor control in a pre-clinical colorectal cancer model.”
BackgroundSTING agonist-based ER-targeting molecules boost antigen cross-presentation
Wang, X., Huang, Z., Xing, L., Shang, L., Jiang, J., Deng, C., Yu, W., Peng, L., Yang, H., Zheng, X., et al. (2025) · Nature · doi:10.1038/s41586-025-08758-w · Cited by 106
Mutation position is an important determinant for predicting cancer neoantigens
Capietto, A.-H., Jhunjhunwala, S., Pollock, S. B., Lupardus, P. J., Wong, J., Hänsch, L., Cevallos, J., Chestnut, Y., Fernandez, A., Lounsbury, N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190179 · Cited by 110
“These results confirmed that a large majority of candidate neoantigens, as predicted by BA alone, are not antigenic with this vaccine, consistent with previous observations (Gubin et al., 2014; Kreiter et al., 2015; Ott et al., 2017; Sahin et al., 2017; Yadav et al., 2014).”
ResultRecent developments of RNA-based vaccines in cancer immunotherapy
Faghfuri, E., Pourfarzi, F., Faghfouri, A. H., Shadbad, M. A., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1815704 · Cited by 105
“discovered that a significant part of non-synonymous cancer mutations delivered by mRNA was immunogenic and was primarily identified by CD4 T lymphocytes [103].”
BackgroundNeoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 98
“In a study in mice, the Sahin group found surprisingly that vaccinations using long peptides containing predicted CD8 T cell neoepitopes resulted in effective, tumor-directed T cell responses that were vastly dominated by neoepitope-specific CD4 T cell responses (111).”
BackgroundD’Alise, A. M., Leoni, G., Cotugno, G., Troise, F., Langone, F., Fichera, I., Lucia, M. D., Avalle, L., Vitale, R. L., Leuzzi, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10594-2 · Cited by 102
Targeting hydrogen sulphide signaling in breast cancer
Youness, R. A., Gad, A. Z., Sanber, K. S., Ahn, Y. J., Lee, G., Khallaf, E., Hafez, H. M., Motaal, A. A. A., Ahmed, N. M., & Gad, M. Z. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.07.006 · Cited by 100
“Of note, the increase in the expression of HLA-DR (class II MHC), which may expose mutant epitopes render tumor cell more immunogenic [43,64], and co-stimulatory ligands [65] on MCF7 cells as well as the changes in NK ligands and cytokine secretion by MDA-MD-231 cells following CBS/CSE KD may be conducive of more effe…”
BackgroundBrentville, V. A., Metheringham, R. L., Gunn, B., Symonds, P., Daniels, I., Gijon, M., Cook, K., Xue, W., & Durrant, L. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1085 · Cited by 98
Profiling tissue-resident T cell repertoires by RNA sequencing
Brown, S. D., Raeburn, L. A., & Holt, R. A. (2015) · Genome Medicine · doi:10.1186/s13073-015-0248-x · Cited by 94
Immunomodulatory Effects of Radiotherapy
Kumari, S., Mukherjee, S., Sinha, D., Abdisalaam, S., Krishnan, S., & Asaithamby, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218151 · Cited by 106
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
Zuazo, M., Arasanz, H., Bocanegra, A., Fernández, G., Chocarro, L., Vera, R., Kochan, G. T., & Escors, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586907 · Cited by 114
Messenger RNA-Based Vaccines Against Infectious Diseases
Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96
Filley, A. C., Henriquez, M., & Dey, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00453 · Cited by 91
Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 101
“Based on preclinical studies demonstrating the primary delivery of these RNA-LPX to APCs in the spleen and a robust reduction of established tumors [47,63], customized RNA-LPXs were tested in a first phase I clinical trial with advanced stage melanoma patients [46].”
BackgroundMethodNanoparticle mediated cancer immunotherapy
Gupta, J., Safdari, H. A., & Hoque, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.015 · Cited by 101
Alghamri, M. S., McClellan, B. L., Hartlage, C. S., Haase, S., Faisal, S. M., Thalla, R., Dabaja, A. A., Banerjee, K., Carney, S. V., Mujeeb, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680021 · Cited by 99
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 94
“This higher prevalence of MHC class II CDNs compared with class I CDNs is consistent with previous reports and the greaterflexibility of peptide binding in the groove ofMHC class II (24, 25).”
BackgroundResultThe perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97
“The last step is the delivery of neoantigens in an immunogenic formulation that includes peptides complexed with adjuvants [20] or with liposome particles [22]or delivered as an RNA vaccine [22].”
BackgroundResultInfluentialHarnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Vormehr, M., Türeci, Ö., & Sahin, U. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-042617-101816 · Cited by 92
Self-citationHybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA
Siewert, C. D., Haas, H., Cornet, V., Nogueira, S. S., Nawroth, T., Uebbing, L., Ziller, A., Al-Gousous, J., Radulescu, A., Schroer, M. A., et al. (2020) · Cells · doi:10.3390/cells9092034 · Cited by 89
Surgical Tumor-Derived Photothermal Nanovaccine for Personalized Cancer Therapy and Prevention
Li, T., Chen, G., Xiao, Z., Li, B., Zhong, H., Lin, M., Cai, Y., Huang, J., Xie, X., & Shuai, X. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00500 · Cited by 93
Predicting T cell recognition of MHC class I restricted neoepitopes
Koşaloğlu‐Yalçın, Z., Lanka, M., Frentzen, A., Premlal, A. L. R., Sidney, J., Vaughan, K. C., Greenbaum, J., Robbins, P. F., Gartner, J. J., Sette, A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1492508 · Cited by 98
Nam, J., Son, S., Park, K. S., & Moon, J. J. (2021) · Advanced Science · doi:10.1002/advs.202002577 · Cited by 94
An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination
Wang, Y., Gong, N., Ma, C., Zhang, Y., Tan, H., Qing, G., Zhang, J., Wang, Y., Wang, J., Chen, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25197-z · Cited by 92
Scholtalbers, J., Boegel, S., Bukur, T., Byl, M., Goerges, S., Sorn, P., Loewer, M., Sahin, U., & Castle, J. C. (2015) · Genome Medicine · doi:10.1186/s13073-015-0240-5 · Cited by 89
“Somatic tumor mutations that give rise to mutated antigens presented on the cell surface (neo-epitopes) are potent targets for cancer immunotherapy [1, 3].”
BackgroundSelf-citationOpportunities for immunotherapy in microsatellite instable colorectal cancer
Westdorp, H., Fennemann, F. L., Weren, R. D. A., Bisseling, T. M., Ligtenberg, M. J. L., Figdor, C. G., Schreibelt, G., Hoogerbrugge, N., Wimmers, F., & de Vries, I. J. M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1832-7 · Cited by 96
“Mostly, this unique set of mutations, the mutanome, was recognized by CD4+ T cells and a vaccination approach with antigens recognized by CD4+ T cells indeed resulted in strong anti-tumor activity [96].”
BackgroundImmunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
Moehler, M. H., Delic, M., Goepfert, K., Aust, D. E., Grabsch, H. I., Halama, N., Heinrich, B., Julié, C., Lordick, F., Lutz, M. P., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.020 · Cited by 97
“Tailored immunotherapy approaches could exploit the substantial cancer neoepitope repertoire with a patient specific de novo vaccine produced on demand (35).”
BackgroundDeng, W., Lira, V., Hudson, T. E., Lemmens, E. E., Hanson, W. G., Flores, R., Barajas, G., Katibah, G. E., Desbien, A. L., Lauer, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801910115 · Cited by 95
“However, LADD-AH1 treatment failed to induce responses against CT26 neoepitopes whose vaccination were reported to reject CT26 tumor (21) (SI Appendix, Fig.”
BackgroundZhang, X., Goedegebuure, S. P., Chen, M. Y., Mishra, R., Zhang, F., Yu, Y. Y., Singhal, K., Li, L., Gao, F., Myers, N. B., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01388-3 · Cited by 98
Veatch, J. R., Jesernig, B. L., Kargl, J., Fitzgibbon, M., Lee, S. M., Baik, C., Martins, R., Houghton, A. M., & Riddell, S. R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0402 · Cited by 89
“Neoantigen vaccination strategies in murine models suggest that CD4þ responses to neoantigens are more prevalent and potentially more effective in antitumor immunity than CD8þ T-cell responses (15).”
BackgroundSubcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy
Kuai, R., Sun, X., Yuan, W., Xu, Y., Schwendeman, A., & Moon, J. J. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00761 · Cited by 87
Footprints of antigen processing boost MHC class II natural ligand predictions
Barra, C., Alvarez, B., Paul, S., Sette, A., Peters, B., Andreatta, M., Buus, S., & Nielsen, M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0594-6 · Cited by 88
pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
Zhou, C., Wei, Z., Zhang, Z., Zhang, B., Zhu, C., Chen, K., Chuai, G., Qu, S., Xie, L., Gao, Y., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0679-x · Cited by 99
Balta, E., Wabnitz, G. H., & Samstag, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115736 · Cited by 88
Fiedler, K., Lazzaro, S., Lutz, J., Rauch, S., & Heidenreich, R. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_5 · Cited by 97
Takeuchi, Y., Tanemura, A., Tada, Y., Katayama, I., Kumanogoh, A., & Nishikawa, H. (2018) · International Immunology · doi:10.1093/intimm/dxx073 · Cited by 86
Zeng, B., Middelberg, A. P. J., Gemiarto, A. T., MacDonald, K. P. A., Baxter, A. G., Talekar, M., Moi, D., Tullett, K. M., Caminschi, I., Lahoud, M. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96791 · Cited by 90
“POT) (41) was carried out using monocytes isolated by a 2-hour plastic”
Cancer Vaccines: Antigen Selection Strategy
Zhao, Y., Baldin, A. V., Isayev, O., Werner, J., Zamyatnin, A. A., & Bazhin, A. V. (2021) · Vaccines · doi:10.3390/vaccines9020085 · Cited by 98
Qiu, F. X., Becker, K. W., Knight, F. C., Baljon, J. J., Sevimli, S., Shae, D., Gilchuk, P., Joyce, S., & Wilson, J. T. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.052 · Cited by 89
Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype
Pascolo, S. (2021) · Viruses · doi:10.3390/v13020270 · Cited by 87
“, in combination with other cancer treatments) will surely lead to the validation of anti-cancer ivt mRNA vaccines [21,22].”
BackgroundMao, C., Beiss, V., Fields, J. L., Steinmetz, N. F., & Fiering, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120914 · Cited by 88
The current clinical landscape of personalized cancer vaccines
Fritah, H., Rovelli, R., Chiang, C. L.-L., & Kandalaft, L. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102383 · Cited by 86
Therapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 89
“synonymous cancer mutation preferentially led to the induction of CD4 Tcells mediating tumor regression [117, 118].”
BackgroundEfficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L., Yan, L., Long, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 85
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 94
“The integration of advanced bioinformatics tools has also contributed to the acceleration of vaccine development and production, enabling more rapid clinical translation and patient access [110].”
BackgroundNeoepitopes of Cancers: Looking Back, Looking Ahead
Srivastava, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0134 · Cited by 88
“Kreiter and colleagues (51) suggest that "the less stringent length and sequence requirements for peptide binding to MHC II" may be responsible for the high proportion of mutations that generate MHC II–restricted neoepitopes.”
BackgroundSteatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice
Heinrich, B., Brown, Z. J., Diggs, L. P., Vormehr, M., Ma, C., Subramanyam, V., Rosato, U., Ruf, B., Walz, J. S., McVey, J. C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.031 · Cited by 82
Self-citationT‐cell subsets in the skin and their role in inflammatory skin disorders
Krohn, I. K., Aerts, J. L., Breckpot, K., Goyvaerts, C., Knol, E. F., van Wijk, F., & Gutermuth, J. (2021) · Allergy · doi:10.1111/all.15104 · Cited by 94
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 97
“Besides BNT122, some vaccines originated from BioNTech have promising therapeutic effects in preclinical cancer models [123,124] and are currently in the early stages of clinical evaluation for breast cancer (NCT02316457) and melanoma (NCT04526899, phase II).”
BackgroundMAGE-A Antigens and Cancer Immunotherapy
Zajac, P., Schultz‐Thater, E., Tornillo, L., Sadowski, C., Trella, E., Mengus, C., Iezzi, G., & Spagnoli, G. C. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00018 · Cited by 87
Neoantigen-based cancer immunotherapy
Bobisse, S., Foukas, P. G., Coukos, G., & Harari, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.17 · Cited by 84
“Moreover, other key aspects that deserve more in-depth studies are the role of neoAg-specific CD4 T cells that have been shown to represent the main component of antineoAg reactivities in some tumors (9,10,23), the role of the tumor microenvironment and the relative contribution of phenomena of tumor editing and Ag sp…”
BackgroundResultInfluentialAnti‐programmed cell death‐1 therapy in nonmelanoma skin cancer
Winkler, J. K., Schneiderbauer, R., Bender, C., Sedlaczek, O., Fröhling, S., Penzel, R., Enk, A., & Hassel, J. C. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14664 · Cited by 80
Brightman, S. E., Becker, A., Thota, R. R., Naradikian, M. S., Chihab, L. Y., Zavala, K. S., Premlal, A. L. R., Griswold, R. Q., Dolina, J. S., Cohen, E. E. W., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01543-9 · Cited by 85
Self-citationKim, D.-S., Dastidar, H., Zhang, C., Zemp, F. J., Lau, K., Ernst, M., Rakic, A., Sikdar, S., Rajwani, J., Naumenko, V., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00324-x · Cited by 75
Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy
Laumont, C. M., & Perreault, C. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2628-4 · Cited by 82
Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 91
“Using this dataset, tumor-specific mutations were identified by algorithms and selected vaccine targets were based on their expression levels and major histocompatibility complex (MHC) binding capacity (24, 25).”
BackgroundMethodSignaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
Liu, W. R., & Shipp, M. A. (2017) · Blood · doi:10.1182/blood-2017-06-781989 · Cited by 82
Schmidt, M., Weyer‐Elberich, V., Hengstler, J. G., Heimes, A.-S., Almstedt, K., Gerhold‐Ay, A., Lebrecht, A., Battista, M. J., Hasenburg, A., Şahin, U., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0942-x · Cited by 105
“Nonetheless, most of the immunogenic mutanome is recognized by the CD4+ T cells, and vaccination with CD4+ immunogenic mutations leads to strong antitumor activity [35, 36].”
BackgroundGrandi, A., Tomasi, M., Zanella, I., Ganfini, L., Caproni, E., Fantappiè, L., Irene, C., Frattini, L., Isaac, S. J., König, E., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00253 · Cited by 77
“egFrviiipep and M30 Having demonstrated that EGFRvIII-OMVs induced a robust protection in C57BL/6 mice challenged with B16F10EGFRvIII cell line, we investigated whether protection could be further potentiated by formulating Nm-fHbp-OMVs with B16-M30pep, a second antigen expressed in B16F10EGFRvIII and generated by one…”
BackgroundMethodInfluential
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.